FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer
The Latest: Drug maker CStone Pharmaceuticals (2616.HK) announced on Tuesday its Pralsetinib, also known by the brand name Gavreto, was approved by China’s drug regulator as a first-line treatment for…
CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals
Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped…
RELATED ARTICLES
-
Stock disconnect triggers investor exodus from CStone Pharma
2616.HK -
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
